Table 1 Basic information of included studies for FGFR4 G388R, V10I variants and risk of cancer.

From: Effects of FGFR4 G388R, V10I polymorphisms on the likelihood of cancer

First author G388R	Year	Origin	Cancer	Ethnicity	Source	Case	Control	Case			Control			HWE	Method
First author G388R	Year	Origin	Cancer	Ethnicity	Source	Case	Control	RR	RG	GG	RR	RG	GG	HWE	Method
Wimmer	2019	Germany	HNSCC	European	PB	284	123	12	84	188	8	60	55	0.114	PCR–RFLP
Chen	2018	Taiwan	Cervical cancer	Asianfb	HB	226	335	56	101	69	74	165	96	0.845	TaqMan
Li	2017	China mainland	Cervical cancer	Asian	HB	162	162	48	79	35	40	72	50	0.170	PCR–RFLP
Chou	2017	Taiwan	OSCC	Asian	PB	955	1191	206	524	225	334	596	261	0.873	TaqMan
Sheu	2015	China mainland	HCC	Asian	HB	289	595	57	150	82	122	314	159	0.146	TaqMan
Jiang	2015	China mainland	Breast cancer	Asian	NA	747	716	138	404	205	98	348	270	0.398	Snapshot
Ture	2015	Turkey	Lung cancer	European	HB	124	100	11	47	66	6	46	48	0.242	PCR–RFLP
Gao	2014	China mainland	NHL	Asian	NA	421	486	115	189	117	75	240	171	0.541	PCR–RFLP
Shen	2013	China mainland	Gastric cancer	Asian	PB	304	392	62	124	118	72	188	132	0.724	Sequencing
Heinzle	2012	Austria	CRC	European	PB	85	1660	10	33	42	135	723	802	0.114	TaqMan
Yang	2012	China mainland	HCC	Asian	HB	711	740	144	351	216	132	361	247	0.996	TaqMan
Batschauer	2011	Brazil	Breast cancer	Latin	PB	68	85	3	26	39	3	35	47	0.249	PCR–RFLP
Ho	2010	UK	Prostate cancer	European	PB	397	291	32	182	183	24	117	150	0.860	TaqMan
Tanuma	2010	Japan	OSCC	Asian	HB	150	100	28	53	69	10	48	42	0.487	PCR-SSCP
FitzGerald	2009	USA	Prostate cancer	European	PB	1254	1251	123	544	587	124	496	631	0.070	SNPlex
FitzGerald	2009	USA	Prostate cancer	African	PB	146	80	3	39	104	2	18	60	0.646	SNPlex
Ho	2009	Singapore	HCC	Asian	PB	58	88	14	17	27	20	38	30	0.241	Sequencing
Naidu	2009	Malaysia	Breast cancer	Asian	HB	387	252	36	172	179	15	105	132	0.322	PCR–RFLP
Nan	2009	USA	Skin cancer	European	PB	768	833	78	325	365	84	343	406	0.359	TaqMan
Ma	2008	Japan	Prostate cancer	Asian	HB	492	179	133	196	163	25	87	67	0.701	PCR–RFLP
Mawrin	2006	Germany	Glioma	European	HB	94	25	4	51	39	2	13	10	0.428	PCR–RFLP
Spinola	2005	Italy	Lung cancer	European	HB	274	401	22	104	148	40	168	193	0.699	Pyrosequencing
Spinola	2005	Italy	Breast cancer	European	HB	142	220	20	55	67	25	83	112	0.117	Pyrosequencing
Spinola	2005	Italy	CRC	European	HB	179	220	18	63	98	25	83	112	0.117	Pyrosequencing
Wang	2004	USA	Prostate cancer	European	PB	284	97	42	117	125	4	40	53	0.291	PCR–RFLP
Wang	2004	USA	Prostate cancer	European	PB	45	94	2	6	37	0	18	76	0.305	PCR–RFLP
Morimoto	2003	Japan	Sarcomas	Asian	NA	143	102	17	72	54	13	50	39	0.624	PCR–RFLP
Bange	2002	Russia	Breast cancer	European	PB	61	123	7	28	26	8	60	55	0.114	PCR–RFLP
Bange	2002	Germany	Breast cancer	European	PB	84	123	9	34	41	8	60	55	0.114	PCR–RFLP
Bange	2002	Italy	CRC	European	PB	82	123	7	38	37	8	60	55	0.114	PCR–RFLP
V10I								II	IV	VV	II	IV	VV
Chen	2018	Taiwan	Cervical cancer	Asian	HB	227	335	61	105	61	76	168	91	0.927	TaqMan
Chou	2017	Taiwan	OSCC	Asian	PB	955	1191	228	514	213	326	580	285	0.391	TaqMan
Jiang	2015	China mainland	Breast cancer	Asian	NA	747	716	168	408	171	226	364	126	0.322	Snapshot
Sheu	2015	China mainland	HCC	Asian	HB	289	595	64	160	65	144	300	151	0.835	TaqMan
Nan	2009	USA	Skin cancer	European	PB	753	821	41	251	461	43	271	507	0.390	TaqMan
FitzGerald	2009	USA	Prostate cancer	European	PB	1259	1254	72	405	782	65	447	742	0.827	SNPlex
FitzGerald	2009	USA	Prostate cancer	African	PB	147	80	0	15	132	0	10	70	0.551	SNPlex

CRC, colorectal cancer; HCC, hepatocellular carcinoma; HNSCC, head and neck squamous cell carcinoma; OSCC, oral squamous cell carcinoma; HB, hospital-based; HWE, Hardy–Weinberg equilibrium of controls; NHL, non-Hodgkin's lymphoma; NA, not available; PCR–RFLP, polymerase chain reaction and restrictive fragment length polymorphism; PB, population-based.

Back to article page

Table 1 Basic information of included studies for FGFR4 G388R, V10I variants and risk of cancer.

Search

Quick links